EUVIMEDEUVIMED entdecken
Open Access

A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes

Xin Wang, Iris Broce, Yuqi Qiu, Kacie D Deters, Chun Chieh Fan, Anders M Dale, Steven D Edland, Sarah J Banks, Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & Dementia · 2023

DOI: 10.1002/alz.12952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Xin Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of California, San Diego, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Identifying individuals who are most likely to accumulate tau and exhibit cognitive decline is critical for Alzheimer's disease (AD) clinical trials.

Methods

Participants ( N = 235) who were cognitively normal or with mild cognitive impairment from the Alzheimer's Disease Neuroimaging Initiative were stratified by a cutoff on the polygenic hazard score (PHS) at 65th percentile (above as high‐risk group and below as low‐risk group). We evaluated the associations between the PHS risk groups and tau positron emission tomography and cognitive decline, respectively. Power analyses estimated the sample size needed for clinical trials to detect differences in tau accumulation or cognitive change.

Results

The high‐risk group showed faster tau accumulation and cognitive decline. Clinical trials using the high‐risk group would require a fraction of the sample size as trials without this inclusion criterion.

Discussion

Incorporating a PHS inclusion criterion represents a low‐cost and accessible way to identify potential participants for AD clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumanstau ProteinsBrainBiomarkersPositron-Emission TomographyCognitionAmyloid beta-Peptides

Stichwörter der Autor:innen

Alzheimer's diseaseclinical trialspolygenic hazard scoretau positron emission tomography

Substanzen

tau ProteinsBiomarkersAmyloid beta-Peptides

Autor:innen und Institutionen

  • University of California, San Diego, California, USA.
  • East China Normal University, Shanghai, China.
  • University of California, Los Angeles, California, USA.

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • National Institutes of Health

Zitieren

APA

Wang, X., Broce, I., Qiu, Y., Deters, K. D., Fan, C. C., Dale, A. M., Edland, S. D., Banks, S. J., & Alzheimer's Disease Neuroimaging Initiative (2023). A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes. Alzheimer's & Dementia. https://doi.org/10.1002/alz.12952

Vancouver

Wang X, Broce I, Qiu Y, Deters KD, Fan CC, Dale AM, et al. A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes. Alzheimer's & Dementia. 2023. doi:10.1002/alz.12952

BibTeX
@article{Wang2023,
  author = {Wang, Xin and Broce, Iris and Qiu, Yuqi and Deters, Kacie D and Fan, Chun Chieh and Dale, Anders M and Edland, Steven D and Banks, Sarah J and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  doi = {10.1002/alz.12952}
}
Kostenlos starten →